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Abstract
Hepatitis A virus is a common infectious etiology of acute hepatitis worldwide. 
It was not until World War II (1973) when hepatitis A virus was first identified 
by an American virologist, Stephen Mark Feinstone. The virus is most commonly 
transmitted through contaminated food, water, or sexual contact (oral-anal sex). 
The discovery of hepatitis A virus vaccine is considered a milestone in the history 
of acute viral hepatitis. Hepatitis A occurs worldwide and frequent outbreaks have 
been reported over the years. Major geographic differences have existed in ende-
micity of the disease depending primarily upon hygiene and sanitation practices. 
Some countries have experienced shifting of endemicity due to improvement of 
environmental hygiene, swelled International travel and national recommendations 
for hepatitis A vaccination. The age of acquiring hepatitis A virus is also shifting 
toward adolescents and adults. This has led to a more symptomatic disease, since 
hepatitis A infection among children is usually asymptomatic; this is known as the 
paradox of Hepatitis A epidemiology.
Keywords: acute hepatitis, vaccine, feco-oral route, men who have sex with men, 
outbreak, sero-prevalence, paradox of hepatitis A
1. Introduction
The discovery of hepatitis viruses is one of the most mesmerizing scientific 
escapades of the last five decades. Their identification has been considered a mile-
stone that revolutionized modern day medicine [1]. Disease outbreaks resembling 
hepatitis A have been known since ancient times. The earliest accounts of conta-
gious jaundice are traced to ancient China [2]. Feinstone et al. were first to identify 
Hepatitis A virus (HAV) in the year 1973 [3]. Increasing globalization poses fresh 
challenges for prevention of HAV infections. This chapter is an attempt to decipher 
the evolution of the disease over the years and summaries the current HAV situation 
around the world.
2. The breakthrough
Outbreaks resembling hepatitis A have been reported from Europe in the 17th 
and 18th centuries during the period of war. The pathologists Bamberger and 
Virchow proposed the name “catarrhal jaundice”, as they believed the disease to 
be caused by mucus blockage of common bile duct [4]. Viral origin of the disease 
was first indicated by McDonald [5]. The virus was identified when the focus of 
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investigation changed from serum to feces [6]. It was first seen under immune 
electron microscope in fecal suspension from infected Joliet prison inmates [3].
It was not until early 1900s that the mode of transmission of hepatitis A was 
identified [7, 8]. Although person-to-person contact was evident, the virus was 
thought to spread via droplet nuclei [9, 10]. Voegt successfully transmitted hepatitis 
A through duodenal juice. He published his findings in Munich Medical Weekly 
in 1942 [11]. Havens et al., at Yale University, United States of America, success-
fully transmitted jaundice by feeding serum and stool filtrate to 12 volunteers 
[12]. The differentiation between infectious hepatitis and serum jaundice was 
provided by a series of experiments carried out among mentally disabled residents 
at the Willowbrook State School, Staten Island [13]. While, it was MacCallum who 
proposed the terms hepatitis A and hepatitis B in the year 1947 [14]. The virus was 
first cultured in the year 1979 [15]. The viral genome was identified by reverse-
transcriptase polymerase chain reaction. The cDNA copy was molecularly cloned. 
The RNA transcripts derived from cDNA clone proved infectious in cell cultures 
[16]. Figure 1 depicts the timeline of Hepatitis A virus.
3. Hepatitis A virus – structure and mode of transmission
3.1 Structure
HAV is classified in the family Picornaviridae and genus Hepatovirus. HAV is 
a non-enveloped, 27- to 28-nm spherical virus with icosahedral symmetry. The 
virus contains a positive-sense, single stranded linear RNA. The 5′ end of the viral 
genome consists of a covalently bound protein termed VPg typical of picornaviri-
dae. The viral genome consists of 60 copies each of its 3 major structural proteins, 
namely, VP1, VP2, and VP3 (1D, 1B, and 1C). Although a variety of genotypes 
Figure 1. 
The timeline of Hepatitis A virus.
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(genogroups I–VII) have been identified by analysis of genome sequences, the virus 
has a single serotype. Individual strains of HAV have differences at the molecular 
level that may be useful for epidemiologic studies; however, a high degree of 
identity in nucleic acid (as high as 90%) and amino acid sequence (as high as 98%) 
is generally seen between strains [17, 18].
3.2 Mode of transmission
3.2.1 Feco-oral
HAV is a common infectious etiology of acute hepatitis worldwide. It is most 
commonly transmitted through the feco-oral route. Although, HAV contamination 
of food material can occur anytime during cultivation/preparation/distribution, 
it occurs most commonly during food distribution due to infectious food handlers 
[19]. Virtually any food may be contaminated with the virus. HAV is relatively 
resistant to extremes of temperature and pH. Hepatitis A virus is omnipresent; it 
can perpetuate on environmental surfaces, hands of food handlers, sewage as well 
as in a variety of food products [20].
3.2.2 Parenteral
Rare reports of transfusion related hepatitis A have been published over the 
years. Transmission is via blood/blood products (Factor VIII and IX) collected from 
an infected donor during the phase of viremia [21–23].
3.2.3 Sexual transmission
Studies have found that people who engage in sex with casual partners, sex in gay 
saunas, oral-anal intercourse and household or sexual contact with acute hepatitis 
A (AHA) patients are at increased risk of HAV infection. Several reports of HAV 
infections have been reported among men who have sex with men (MSM) [24–28].
4. HAV vaccine – the holy grail
The discovery of hepatitis A virus, its propagation in cell culture and cloning of 
its genome culminated almost two decades later in the development and licensing 
of an effective vaccine [29, 30]. According to the WHO, the most effective way to 
prevent HAV infection is to improve sanitation and immunization. Gamma globulin 
was found to be effective in prevention of measles in susceptible household contacts 
in the year 1944 [31]. Joseph Stokes, a pediatrician working at the University of 
Pennsylvania School of Medicine, used the knowledge in curtailing hepatitis A 
outbreak among children by administering gamma globulins [32].
First HAV vaccine was developed in early 1900 [33, 34]. In 1991, a preliminary 
study was published among vaccinees, demonstrating neutralizing antibodies 
following the administration of formalin-inactivated vaccines [35]. Live attenuated 
hepatitis A vaccine was developed subsequently [36].
By 1992, the clinical efficacy of two formalin-inactivated hepatitis A vaccines 
HAVRIX (Smith-Kline Beecham) and VAQTA (Merck, Sharpe and Dohme) became 
obvious [30, 33]. Two laboratory-attenuated strains HM175 and CR326F respectively 
were used for vaccine production. The adverse reactions following vaccination were 
minimal, and seroconversion after two doses was found to be quite high (99.8%) [30]. 
Other monovalent formalin inactivated HAV vaccines available in market today 
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Table 1. 
List of HAV vaccines available in market.
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include AVAXIM (Aventis Pasteur), HEALIVE (Sinovac Biotech Co Ltd), Weisairuian 
(Institute of Medical Biology of the Chinese Academy of Medical Sciences; Kunming), 
Veraxim (Shanghai Wison Bioengineering Inc) and EPAXAL (Crucell/Berna Biotech). 
Hepatitis A vaccine is also available as a combined preparation with Hepatitis B vaccine 
in the form of TWINRIX (GlaxoSmithKline) Table 1 [37–39].
The Food and Drug Administration (FDA) licensed HAVRIX in February 1995 
for children (≥2 years), adults and travelers [34]. Centers for Disease Control and 
Prevention recommends vaccination for children 12 months or older, travelers 
to endemic countries, gays, illegal drug users, individuals with occupational risk 
exposure and chronic liver disease patients. The American College of Physicians too 
also recommends vaccination of high-risk groups [40].
In the United States, vaccination against hepatitis A is available as inactivated, 
monovalent vaccines (HAVRIX and VAQTA) or in combination with hepatitis 
B (TWINRIX). These vaccines are highly efficacious with seroconversion rates 
approaching 100% [41]. With the implementation of vaccination, the incidence 
of HAV in the United States has shown a drastic decline of 92% (12 cases per 
100,000 in 1995 to 1 case per 100,000 in 2007) [42].
Among the developing nations, Indian Academy of Pediatrics (IAP) recom-
mends two doses of vaccine for children (≥1 year). The recommended dose is 720 
ELISA Units (ELU) for <19 years and 1440 ELU for ≥19 years. Protective antibody 
titers are seen in almost 100% vaccinees following the second dose [43]. No major 
adverse reactions have been associated with vaccine use.
CDC recommends vaccine instead of immunoglobulin for exposure to HAV in 
healthy individuals aged 1 to 40 years. Standard adult dosing recommends adminis-
tration of two doses of the vaccine 6–12 months apart. For individuals 41 years and 
older, immunoglobulin administration is preferred due to the risk of more severe 
clinical presentation and limited evidence of vaccine efficacy in this age group. 
Immunoglobulins are also recommended for children less than 12 months, individu-
als with chronic liver disease, and immunocompromised patients [44–46].
5. HAV epidemiology – pre-vaccine era and the paradox of vaccine era
5.1 The pre-vaccine era
In the pre-vaccine era, hepatitis A occurred in cycles, every 10–15 years, 
with majority of cases reported among children (≤15 years) [47, 48]. Most cases 
(12–25%) of hepatitis A in the United States occurred as communitywide epidem-
ics in which infection was transmitted from person to person among household 
or sexual contacts. International travel and foodborne outbreaks accounted for a 
small percentage of cases [49]. Asymptomatic infections among children played an 
important role in sustaining transmission. According to a survey conducted in the 
United States of America (1988–1994), a third of the population were sero-positive 
for anti-HAV IgG antibodies [50]. In the developing part of the world, majority of 
the population acquires asymptomatic hepatitis A infection early in life, such that 
large proportion of population is immune to HAV [51, 52].
HAV infection resulted in devastating consequences in susceptible populations. 
An outbreak in Shanghai, China in 1988 affecting over 300,000 people due to 
consumption raw clams represents an example of the magnitude problem in the 
pre-vaccine era [53].
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5.2 The vaccine era
5.2.1 The world scenario – HAV sero-prevalence
WHO estimates that approximately 1.5 million people are infected with HAV each 
year [54]. The incidence of HAV in a given population correlates with socioeconomic 
properties such as income, density of housing, sanitation, and water quality. Endemic 
rates are high in developing countries with poor sanitation and hygiene practices. 
HAV endemicity is classified into low, intermediate, and high based on the sero-
prevalence of anti-HAV IgG (<15%, 15–50% and >50%) [37]. High sero-prevalence 
reflects that majority of the population is immune to HAV [55]. HAV in children 
is usually asymptomatic, while frank hepatitis is seen when HAV infection occurs 
in adults. Since 1999 several countries including, southern Asia, Latin America, 
and Europe, have experienced a decline in the incidence of HAV infection due to 
improved sanitation and routine vaccination. This has resulted in a higher incidence 
of HAV infection among adult population [56–61]. The shift in age group, which 
acquires hepatitis A, towards adolescents and adults has amplified the incidence of 
symptomatic disease, since childhood HAV infection is usually asymptomatic [51, 52].
Since the availability of HAV vaccine, an overall increase in the incidence of 
reported HAV cases has been observed from European Union countries [62]. This 
points to new risks associated with globalization and population migration [62, 63]. 
According to a health survey conducted in the USA, a significant decrease in HAV 
immunity among adult population was noted between 1988–1994 and 1999–2006 
[64]. The survey also demonstrated rise in the rate of hospitalization among HAV 
infected individuals, consequent to a higher percentage of symptomatic infection 
among adult population over the last decade [65]. This is known as the “paradox of 
hepatitis A risk” [55].
Prognosis of HAV is usually good among younger population, with low mortal-
ity rates (0.1%). The mortality rate increases proportionately with age, to as high 
as 2.1% among ≥40 years old [66]. In developing world, including Asia, Africa and 
South America, evidence of past infection is nearly universal. Juxtapose to this, 
infection rates are low in developed countries such as the United States, Canada, and 
Europe. High-risk  groups in these regions comprise of injection drug users, homo-
sexuals, people traveling to endemic regions, and among isolated communities such 
as nursing homes etc. [67].
In the USA, HAV outbreaks were common among illicit drug users in the pre-
vaccine era. Drug users accounted for over 20% of all HAV cases as reported by the 
CDC during mid-1980s [68, 69]. Since 1999, with the implementation of routine 
HAV vaccination program, hepatitis A incidence has shown a steady decline until 
2011 [70, 71]. The incidence has stabilized at an annual average of over a 1000 cases 
per year. Most cases were reported among international travelers returning from 
countries endemic for HAV [72].
In a sero-prevalence study conducted among military personals in France, 
Lagarde found the prevalence of HAV antibodies as 16.3% [73]. Another study con-
ducted in Korea found the overall HAV sero-prevalence of 63.8% [74]. Japan has been 
conducting sero-prevalence studies over the years. The overall HAV sero-prevalence 
has dramatically decreased from 96.9% in 1973 to 96.9% in 1984 and 12.2% in 2003. 
Notably, the population susceptibility increased annually [75]. A sero-prevalence 
survey in Taiwan during 2009–2010 showed that only 10% of MSM aged 18–40 years 
in Taiwan had anti-HAV antibodies [76]. HAV vaccination program was imple-
mented in Taiwan in 2016. Although this lead to decline in the frequencies of both 
human cases and positive sewage samples, no substantial increase in vaccination 
coverage was seen among high risk groups like MSM and HIV-infected patients [77].
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Exposure to HAV is virtually universal before the age of 10 years in most devel-
oping countries [78]. In a study conducted in rural Liberia, an annual incidence of 
HAV was reported to be 45% among children aged 1–5 years [79]. In Indonesia, 95% 
of children, under the age of 10 years, were naturally immune to HAV infection 
[80]. Above-mentioned studies point towards the fact that, mass HAV vaccination 
might not be necessary in highly endemic regions.
In India, the sero-prevalence of anti-HAV antibodies exceeds 90% among adults 
[81]. However, there have been recent reports of a decreasing sero-prevalence 
across the country, paralleling with the industrialized world [82, 83]. Accordingly, 
HAV vaccination has been recommended for school children as well as adults [84]. 
Another study conducted among children found the age-related sero-prevalence 
of HAV to be 50.3% in the age group of 6–10 years and 30.3% among 18 months to 
6 years of age. The HAV prevalence correlated strongly with the child’s education 
and socioeconomic status [85]. In another Indian study, the HAV prevalence was 
found to be 97.2% [78]. These findings were in agreement with the expected pattern 
of HAV sero-prevalence in an area of high endemicity. Similar findings have been 
reported from other parts of the country as well [86–88].
About 90% of Indian children acquire protective antibodies against HAV by the 
age of 10 years. Similar patterns of endemicity have been found in other developing 
countries, with high sero-prevalence of anti-HAV antibodies [89]. Surveys con-
ducted among children in Egypt have also reported almost 100% sero-prevalence 
rates [90].
Several studies from India have recently reported a significant sero-epidemio-
logical shift, with increasing incidence of infection among adults and adolescents. 
Recently in New Delhi, anti-HAV antibody prevalence among adults was reported 
to be as low as 36.7% [82].
Chile and Jordan have reported a decrease in anti-HAV sero-prevalence over the 
years [89, 91]. The study conducted in Jordan showed a continual rise of the sero-
prevalence rates with rise in age. While, sero-prevalence was 26% among <2 years 
old, the rate increased to a whooping 94% for >20 years old [91]. A study conducted 
in Western Brazil revealed overall sero-prevalence among children as 16.7% in the 
year 2011, which significantly increased to 70.45% in a recently conducted survey 
[52, 91]. This high prevalence might be attributed to disease outbreaks in few parts 
of the district of Gampaha.
5.2.2 HAV outbreaks over the last decade
Over the last 10 years, several outbreaks have been reported throughout the 
world Table 2 and Figure 2 [92–107].
Although feco-oral route has been implicated in most of the cases, sexual mode 
of transmission among high risk groups is the second most prevalent route of 
transmission [104, 105].
In 2016, about 2000 cases of HAV were reported in the United State [92]. CDC 
and FDA investigated two major HAV outbreaks due to consumption of contami-
nated foods (strawberries imported from Egypt and scallops from Philippines). The 
first outbreak affected 134 people, with two hospitalization while, the second out-
break affected 292 individuals with 94 hospitalizations [93, 94]. An HAV outbreak 
in California in 2017 encompassed homelessness individuals and illicit drug users 
with poor sanitation practices. The outbreak spread to several other states as well. A 
total of 694 individuals were infected, with 45 hospitalizations and 21 deaths [95].
A sizeable hepatitis A outbreak was reported in Australia in 2009, resulting in 
a 2-fold increase in the number of cases reported to the state health departments. 
Surveillance data suggested infection due to contaminated semidried tomatoes [96].
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A total of 32 outbreaks of water/food-borne disease outbreaks were reported 
from Kerala, India alone, in the same year, involving 2421 cases. All these outbreaks 
were attributable to feco-oral route [97]. Around 223 hepatitis A cases were identi-
fied in a HAV outbreak in Kerala. Attack rate was found to be highest among the age 
group of 16–30 years (1.44%). Food/water from a newly opened hotel in the area 
was the possible source of the outbreak [101]. In another study, authors reported 
Figure 2. 
Hepatitis A outbreaks throughout the world over the last decade.
Table 2. 
Hepatitis A outbreaks around the world over the last decade.
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HAV outbreak in the medical college area in Kottayam [100]. Another outbreak of 
acute hepatitis was reported from Mylapore village, Kollam district, southern India 
during February to June 2013. A total of 45 cases were affected, pipe water contami-
nation from a bore well was identified as the source [101].
In a study conducted among acute viral hepatitis patients in North India, hepati-
tis A virus was identified as the most common etiological agent (26.96%) followed 
by hepatitis E virus [99].
Gassowski et al. reported two hepatitis A outbreaks in Europe. One affect-
ing travelers returning from Morocco and the other among European residents 
without travel history. The outbreaks lasted from January to June 2018, affecting 
163 patients in eight European countries. The HAV was genotypically identified 
as belonging to subgenotype IA DK2018-231 and subgenotype IB V18–16428. 
Common risk factor among the cases was found to be unvaccinated travel due to 
lack of awareness [102].
In July 2010, five cases of HAV infection were reported among the Orthodox 
Jewish (OJ) community in London, United Kingdom. Two of the cases gave history 
of travel to Israel for the same event a few days back. A total of 900 contacts of the 
cases were traced and vaccinated [106].
Cyclic outbreaks of HAV among high-risk groups (MSM and/ HIV) have been 
described in several reports. Outbreak strains among MSM across countries were 
found to be genetically alike and circulated for over a decade [104, 105]. In June 
2015, a considerable increase in reports of AHA infection was noted in Taiwan 
mostly affected MSM and patients with HIV or other STI. The strain was later 
identified as TA-15 strain. In 2016, multi-country HAV outbreaks predominately 
affecting MSM were observed in Europe. The EuroPride strain (RIVM-HAV16–090) 
detected was genetically quite similar to the TA-15 strain identified earlier [87, 108]. 
A similar outbreak strain was also reported in the United States in 2017 [103], which 
suggests a global pattern of increased risk among susceptible male adults, with 
possible transmission through sexual contacts at MSM events.
6. Conclusion
HAV adversely affects the economy of a country by decreasing productivity of 
its citizens due to absenteeism from work, adding to medical costs and the effect 
on tourism. Improving sanitary conditions and providing clean drinking water are 
imperative pillars in curtailing spread of HAV. Simple method like hand hygiene is 
an effective way to prevent virus transmission. Vaccination forms the foundation in 
prevention of HAV. Both inactivated and live attenuated vaccines are licensed and 
available for use. Improved sanitation and vaccination although prevents Hepatitis 
A infection, it paradoxically increases the susceptibility of adult population towards 
a more symptomatic disease. This vicious cycle is the dilemma of HAV control and 
prevention program.
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